Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MUSTANG BIO, INC.MBIO · Entity 8350 | Director | July 05, 2023 | July 07, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MUSTANG BIO, INC.
Report date July 05, 2023 · Filed July 07, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| COMMON STOCK, PAR VALUE $0.0001SEC Table I · non-derivative | Direct | 18,970 |
Reported balance
After 2023-07-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-07-05 · Grant · Acquired 7,246 · Balance 18,970 F1: The Reporting Person was granted 7,246 restricted shares pursuant to the Issuer's 2016 Incentive Plan on July 5, 2023. The shares will vest on July 5, 2026, subject to the Reporting Person's continued service on the Issuer's board on such date. F2: Effective April 3, 2023, the Issuer effected a fifteen-for-one reverse stock split of its common stock (the "Reverse Stock Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Stock Split. F3: Includes restricted share units, which vest over various time periods. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted 7,246 restricted shares pursuant to the Issuer's 2016 Incentive Plan on July 5, 2023. The shares will vest on July 5, 2026, subject to the Reporting Person's continued service on the Issuer's board on such date.
F2: Effective April 3, 2023, the Issuer effected a fifteen-for-one reverse stock split of its common stock (the "Reverse Stock Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Stock Split.
F3: Includes restricted share units, which vest over various time periods.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 05, 2023 Filed Jul 7, 2023 16:07 UTC | MUSTANG BIO, INC. MBIO · Entity 8350 | GrantCOMMON STOCK, PAR VALUE $0.0001 | 7,246 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-079118 · tm2320790-6_4seq1.xml · nonDerivative · entry 1 ZELEFSKY MICHAEL J · CIK 0001266801 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,970 F1 · shares: The Reporting Person was granted 7,246 restricted shares pursuant to the Issuer's 2016 Incentive Plan on July 5, 2023. The shares will vest on July 5, 2026, subject to the Reporting Person's continued service on the Issuer's board on such date. F2 · shares: Effective April 3, 2023, the Issuer effected a fifteen-for-one reverse stock split of its common stock (the "Reverse Stock Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Stock Split. F2 · balance_after: Effective April 3, 2023, the Issuer effected a fifteen-for-one reverse stock split of its common stock (the "Reverse Stock Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Stock Split. F3 · balance_after: Includes restricted share units, which vest over various time periods. Read SEC document |
| July 29, 2022 Filed Apr 3, 2023 16:49 UTC | MUSTANG BIO, INC. MBIO · Entity 8350 | GrantCOMMON STOCK, PAR VALUE $0.0001 | 71,664 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-040927 · tm2311237d3_4seq1.xml · nonDerivative · entry 1 ZELEFSKY MICHAEL J · CIK 0001266801 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,861 F1 · shares: The Reporting Person was granted 71,664 restricted shares pursuant to the Issuer's 2016 Incentive Plan on July 29, 2022. The shares will vest on June 17, 2025, subject to the Reporting Person's continued service on the Issuer's board on such date. F2 · balance_after: Includes restricted share units, which vest over various time periods. Read SEC document |
| June 28, 2021 Filed Jul 8, 2021 16:33 UTC | MUSTANG BIO, INC. MBIO · Entity 8350 | GrantCOMMON STOCK | 13,774 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-090248 · tm2121675-6_4seq1.xml · nonDerivative · entry 1 ZELEFSKY MICHAEL J · CIK 0001266801 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,197 F1 · shares: The Reporting Person was granted 13,774 restricted shares pursuant to the Issuer's 2016 Incentive Plan on June 28, 2021. The shares will vest on June 17, 2024, subject to the Reporting Person's continued service on the Issuer's board on such date. F2 · balance_after: Includes restricted share units, which vest over various time periods. Read SEC document |
| July 14, 2020 Filed Aug 19, 2020 16:33 UTC | MUSTANG BIO, INC. MBIO · Entity 8350 | GrantCommon Stock | 16,611 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-096928 · tm2028955d5_4.xml · nonDerivative · entry 1 ZELEFSKY MICHAEL J · CIK 0001266801 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,423 F1 · balance_after: 90,423 shares are restricted Common Stock which vest over various time periods. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.